Real-World Study on Everolimus in Advanced, Progressive Neuroendocrine Tumors Abstract #937

Introduction: Everolimus (EVE) is a valid therapeutic option for neuroendocrine tumors (NETs). However, data in the “real-world” setting outside regulatory trials are scant.
Aim(s): To determine EVE tolerability and efficacy, in relationship with previous treatments, in a compassionate-use program.
Materials and methods: One-hundred and sixty-nine advanced progressive NETs treated with EVE evaluated: 85 pancreatic (pNETs), and 84 non-pancreatic (non-pNETs). Previous treatments were: somatostatin analogs 92.9%, PRRT 50.3%, chemotherapy 49.7%, PRRT and chemotherapy 22.8%.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Targeted therapies
Presenting Author: Francesco Panzuto

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2924 Everolimus in Patients with Advanced Neuroendocrine Neoplasia: A Real-World Study and Analysis of Long Responders
Introduction: Everolimus is a valid therapeutic option for neuroendocrine tumors (NETs); however, data regarding the long responsders in a real-world setting, outside regulatory trials, are scanty.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: MD Maria Rinzivillo
#2785 Inhibition of Cyclin Dependent Kinases Overcomes MYC-Driven Secondary Resistance to Everolimus in Digestive NETs
Introduction: Dysregulation of the mTOR pathway in digestive neuroendocrine tumours (d-NETs) led to the introduction of Everolimus (EVE) as treatment. EVE significantly increases PFS, but most patients acquire resistance, due to activation of feedback loops.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Md, PhD Gabriele Capurso
#1103 Risk and Protective Factors for Midgut Carcinoid Tumours: A Case-Control Study of Prospectively Evaluated Patients
Introduction: The incidence of midgut carcinoid tumours is on the rise, but few studies have investigated risk factors for their occurrence.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Doctor Maria Rinzivillo
#1368 Everolimus in Pancreatic Neuroendocrine Carcinomas G3
Introduction: Neuroendocrine Carcinomas (NEC) G3 are heterogeneous diseases with different behaviors, basing on tumor morphology and Ki67 value. Platinum-based chemotherapy is considered the standard treatment in these pts. However, tumors with well-moderately differentiated morphology (NET G3), with Ki67 < 55% may be considered a separate entity in terms of prognosis and therapeutic options
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Francesco Panzuto
#2812 SILVELUL Project: Development of an New Potential Predictive Immunohistochemical Score (SPI) in Patients (pts) with Pancreatic Neuroendocrine Tumors (PanNET) Treated with CAPTEM or Everolimus
Introduction: Previously our group showed the potential use of a score based on MGMT, NDRG-1 and PHLDA-3 immunohistochemistry (IHC) expression as predictor of outcome in operated PanNET (Viúdez et al. Oncotarget 2016).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD PhD Antonio Viudez